Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the […]
Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]
This 5th Pharmabiotics Conference Edition, hosted by the Pharmabiotic Research Institute, took place Mid-March in Paris and peaked as the most successful to date, with over 190 delegates attending over the 2-day event. As in […]
Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]
This month’s 5-minute microbiome science roundup includes some important papers published this month related to both health and disease. The two colorectal cancer microbiome-related papers published in Nature are a sign that the field is beginning […]
The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA and 4D’s strategic collaboration with MD Anderson has completed Cycle 1 […]
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children […]